Technology | January 05, 2015

FDA Clears Sorin Group Memo 3D ReChord Annuloplasty Ring

Mitral valve annuloplasty ring with chordal guiding system standardizes artificial chord replacement

Sorin Group, Memo 3-D ReChord, annuloplasty ring, mitral valve repair

Image courtesy of Sorin Group

January 5, 2015 — Sorin Group announced U.S. Food and Drug Administration (FDA) clearance for Memo 3-D ReChord, a semi-rigid annuloplasty ring for mitral valve repair.

The device incorporates a chordal guide system into the existing Memo 3-D ring to simplify and standardize the approach to artificial chord replacement. Memo 3-D ReChord’s unique design streamlines mitral repair procedures while allowing surgeons to obtain reproducible results even in advanced chordal reconstructions.

Features include:

  • A unique temporary chordal guide system that simplifies artificial chord replacement
  • Sorin's Carbofilm coating to enhance hemo-compatibility
  • Cell-structure design to accommodate the mitral saddle shape while enabling the physiological 3-D motion of the native annulus.


Steven F. Bolling, M.D., professor of cardiac surgery, University of Michigan Health System, who conducted the first implantation of the ring in the United States, commented on his experience: “The Memo 3D ReChord is simple to use with a minimal learning curve for new users. The chordal guide system gives surgeons more confidence when performing anterior mitral leaflet repairs with Gore-Tex chordae.

I believe that using the Memo 3D ReChord allows surgeons to deliver more reproducible results during this procedure, ultimately improving patient outcomes. Offering a solution that standardizes artificial chord replacement may actually increase the number of anterior mitral leaflet repairs performed each year.”

For more information:

Related Content

Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Overlay Init